Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Clinical trial NCT03486067 · TERMINATED
Trial details
- NCT number
- NCT03486067
- Sponsor
- Celgene
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-03
- Primary completion
- 2025-03-18
- Enrollment
- 183
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.